missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Durvalumab Recombinant Monoclonal Antibody
Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA558379
This item is not returnable.
View return policy
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1 kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
Specifications
| Durvalumab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| Imfinzi; MEDI4736 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 κ |
| ELISA, Flow Cytometry | |
| 1 mg/mL | |
| 25mM histidine with 0.01% Tween 80, 8% sucrose and no preservative; pH 6.2 | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur